Literature DB >> 28670762

Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.

Daniel Kritsch1, Franziska Hoffmann1, Daniel Steinbach1, Lars Jansen1, Stella Mary Photini2, Mieczyslaw Gajda3, Alexander S Mosig4, Jürgen Sonnemann5, Sven Peters6, Margarita Melnikova7, Jürgen Thomale7, Matthias Dürst1, Ingo B Runnebaum1, Norman Häfner1.   

Abstract

Aim was to identify methylated genes with functional involvement in cisplatin-resistance development of epithelial ovarian cancer (EOC). Genome-wide analyses of hypermethylated CpG-islands in resistant cell lines in combination with qRT-PCR analyses were used to identify epigenetically silenced genes. EOC-Type-II tumors were analyzed for gene methylation and expression and TCGA data were interrogated in-silico. Experiments revealed 37 commonly hypermethylated genes in resistant cells of which Tribbles 2 (TRIB2) showed the most pronounced downregulation on mRNA level and was characterized further. TRIB2 showed a reactivation after 5'-Aza-Cytidine treatment in resistant cells but a cisplatin-dependent, prominent upregulation on mRNA level in sensitive cells, only. Re-expression in resistant A2780 cells increased the sensitivity to cisplatin and other DNA-damaging agents, but not taxanes. Contrary, knockdown of TRIB2 increased resistance to cisplatin in sensitive cells. TRIB2 was involved in the induction of a cisplatin-dependent cell cycle arrest and apoptosis by influencing p21 and survivin expression. An increased Pt-DNA-adduct formation in TRIB2 re-expressing cells did not translate in higher levels of dsDNA damage (yH2AX-foci). Thus, TRIB2 is potentially involved in the signal transduction from nucleotide excision repair of intrastrand cross links. Importantly, patient stratification of two homogenous cohorts of EOC-Type-II patients from Jena (n = 38) and the TCGA (n = 149) by TRIB2 mRNA expression consistently revealed a significantly decreased PFS for patients with low TRIB2 levels (log-rank p < 0.05). Tumors from resistant patients expressed the lowest levels of TRIB2. Downregulation of TRIB2 contributes to platin-resistance and TRIB2 expression should be validated as prognostic and predictive marker for EOC.
© 2017 UICC.

Entities:  

Keywords:  DNA damage response; ovarian cancer; platin resistance; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28670762     DOI: 10.1002/ijc.30860

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?

Authors:  Nuno Tiago Tavares; Saulė Gumauskaitė; João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

2.  Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.

Authors:  Guangxu Xu; Ziwei Fang; Leslie H Clark; Wenchuan Sun; Yajie Yin; Rong Zhang; Stephanie A Sullivan; Arthur-Quan Tran; Weimin Kong; Jiandong Wang; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

3.  Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2.

Authors:  Caitriona O'Connor; Krishna Yalla; Mara Salomé; Hothri Ananyambica Moka; Eduardo Gómez Castañeda; Patrick A Eyers; Karen Keeshan
Journal:  Oncotarget       Date:  2018-02-19

4.  A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.

Authors:  Mara Salomé; Aoife Magee; Krisha Yalla; Shahzya Chaudhury; Evgenia Sarrou; Ruaidhrí J Carmody; Karen Keeshan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

5.  TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling.

Authors:  Zhenlin Hou; Kaixuan Guo; Xuling Sun; Fuqing Hu; Qianzhi Chen; Xuelai Luo; Guihua Wang; Junbo Hu; Li Sun
Journal:  Mol Cancer       Date:  2018-12-12       Impact factor: 27.401

Review 6.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 7.  The Critical Role of TRIB2 in Cancer and Therapy Resistance.

Authors:  Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

8.  Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.

Authors:  Li-Yuan Feng; Bing-Bing Yan; Yong-Zhi Huang; Li Li
Journal:  Clin Epigenetics       Date:  2021-07-21       Impact factor: 6.551

Review 9.  A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis.

Authors:  MengMeng Xu; Andreas Seas; Musa Kiyani; Keven S Y Ji; Hannah N Bell
Journal:  Cell Biosci       Date:  2018-04-03       Impact factor: 7.133

10.  CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.

Authors:  Fengbin Gao; Xiaojing Wang; Shanwen Chen; Tianyuan Xu; Xianjin Wang; Yifan Shen; Fan Dong; Shan Zhong; Zhoujun Shen
Journal:  Oncol Rep       Date:  2018-08-10       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.